Tests tozorakimab for uncontrolled asthma in adults using inhaled steroids
Tests tozorakimab injections against placebo in adults with uncontrolled asthma.
Plain-language title generated from the registry record
Registry title: Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Key facts
- Where
- Caxias do Sul, Criciúma, Porto Alegre, Salvador, Santo André, São José do Rio Preto, São Paulo, and Sorocaba, BrazilSee the 8 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-75 whose asthma is not well controlled while on medium or high dose inhaled steroids with a LABA.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Asthma diagnosed by a doctor for at least 12 months and not well controlled (ACQ-6 score ≥ 1.5). Lung function (pre-bronchodilator FEV1) must be ≥ 40% to ≤ 90% of predicted normal.
- Earlier treatment
- Must be treated with medium or high dose ICS (inhaled corticosteroid) together with LABA.
- Biomarker or test result
- Asthma attacks (exacerbations) in the last 12 months: ≥ 2 severe ones, OR 1 severe one plus eosinophils ≥ 150 cells/µl or FeNo ≥ 25 ppb.
Main reasons for not taking part
- Antibiotics for a respiratory infection in the 4 weeks before Visit 1
- Clinically significant lung disease other than asthma
- Current smokers, or former smokers with >10 pack-years
- Active tuberculosis, hepatitis or HIV, or current cancer or immune complex disease
- Unstable heart or circulation disorders, significant aortic stenosis or pulmonary arterial hypertension
Read by machine on 11 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06932263, who can take part
Where in Brazil
- Caxias do SulHospital not named in the registryNo longer taking part
- CriciúmaHospital not named in the registryTaking people
- Porto AlegreHospital not named in the registryTaking people
- SalvadorHospital not named in the registryNo longer taking part
- Santo AndréHospital not named in the registryNo longer taking part
- São José do Rio PretoHospital not named in the registryTaking people
- São PauloHospital not named in the registryTaking people
- SorocabaHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06932263EU 2024-519116-14-00
- Record updated
- 30 October 2026
- Original description
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.Read full original descriptionShow less
A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
Inclusion: Provision of signed and dated written informed consent prior to any study-specific procedures; Adults aged 18-75, inclusive when signing the informed consent; Documented physician-diagnosis of asthma for at least 12 months; Treated with medium or high dose ICS in combination with LABA; Demonstration of uncontrolled asthma through ACQ-6 score ≥ 1.5 ; Pre-bronchodilator FEV1 ≥ 40% to ≤ 90% of predicted normal; Documented exacerbation history in the last 12 months and biomarker requirements of:; ≥ 2 severe exacerbations OR; 1 severe exacerbation and:; (i) Eosinophils ≥ 150 cells/µl or (ii) FeNo ≥ 25 ppb; Participants need to demonstrate a ≥70% compliance for Asthma Daily Diary; Women of Child Bearing Potential (WOCBP) must have a negative pregnancy test; Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion: Completed treatment for respiratory infection with antibiotics in the 4 weeks prior to Visit 1; Clinically significant pulmonary disease other than asthma ; Clinically significant aortic stenosis or pulmonary arterial hypertension; Active tuberculosis, hepatitis, HIV, or current diagnosis of cancer or immune complex disease; Unstable cardiovascular disorders; Current smokers, former smokers with >10 pack-years history.